The three-year collaboration will try to identify biomarkers that can eventually be used for targeted diagnostics and therapies.
The firm previously held rights to develop and commercialize ERAS-0015 in territories outside of China, Hong Kong, and Macau.
The $550 million convertible senior notes offering was upsized from a previously announced offering of $350 million.
The new financing was led by Venrock Healthcare Capital Partners with participation from other new and existing investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results